Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lowering Insulin Costs: Sanofi Seeks HHS Support For Expanding Assistance To Medicare Patients

Executive Summary

HHS endorsement of company-sponsored discount programs for cash-paying customers with Medicare would be preferable to lowering list pricing.

You may also be interested in...



Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing

Sanofi's annual report on its drug price increases echoed a theme heard during recent 2018 earnings calls, with list price hikes offset by rebates resulting in a net price decline.

Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing

Sanofi's annual report on its drug price increases echoed a theme heard during recent 2018 earnings calls, with list price hikes offset by rebates resulting in a net price decline.

Lilly Likes Concept Of Low-Cost Brand Alternatives As ‘Glide Path’ To No Rebates

Approach could be useful for quickly lowering the cost of insulins, Express Scripts’ Miller points out.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel